Obtenga las últimas noticias sobre las acciones de Upstream Bio con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de UPB

Últimas noticias sobre

Upstream Bio

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.

Movimiento de acciones

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHL

ASYS

EFXT

GNFT

HYFM

LFVN

MTUS

RSLS

RVSB

STSS

SUNE

VEEE

VERO

WHLR

ReShape Lifesciences firma acuerdo exclusivo con Motion Informatics y dispara sus acciones antes de la apertura de mercado.

Acciones de ReShape Lifesciences (RSLS) se disparan un 82%; Aquí están 20 acciones que se mueven en premercado

Upstream Bio Inc

Upbound Group Inc

UNITED PLANT BERHAD ORD by United Plantations Berhad

United Plantation Bhd

UpBots

Press Releases

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Health Care

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

Earnings

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

BBNX

BCAX

IMGO

KMTS

MORF

AnaptysBio

Ardelyx

BridgeBio Oncology Therapeutics, Inc. - Common Stock

BridgeBio Oncology

Bicara Therapeutics

CureVac

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Immatics

Kodiak Sciences

MiMedx Group

Nanobiotix

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Prime Medicine

Relay Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Tango Therapeutics

Tourmaline Bio

Vir Biotechnology

Xencor

Zenas BioPharma

Zymeworks

Truist Securities

JP Morgan

Piper Sandler

Comments

Upstream Bio Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL